Physician profile
Norman Wall
NPI 1861416661
$2,088.02
in general payments reported to CMS, 2019-2025
12 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.15 · 2023: $1,563 · 2024: $198 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,339 · Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,338.71 |
| Food and Beverage | $664.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $1,386.57 | 2023 | Argyle |
| Travere Therapeutics, INC. | $236.48 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $144.77 | 2022-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $78.19 | 2022-2024 | |
| Nxstage Medical, INC. | $49.20 | 2022 | |
| Amgen INC. | $37.98 | 2024 | Tavneos, Krystexxa |
| Baxter Healthcare | $36.83 | 2025 | Hillrom - Monarch Airway Clearance System |
| Novartis Pharmaceuticals Corporation | $31.92 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $24.39 | 2024 | Farxiga |
| Glaxosmithkline, LLC. | $21.84 | 2024 | Benlysta |
| Calliditas Therapeutics US INC. | $20.50 | 2025 | Tarpeyo |
| Terumo Medical Corporation | $19.35 | 2024 | Angio-Seal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.